Stock INTS INTENSITY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-07-09 pm EDT 		5-day change 1st Jan Change
4.74 USD -0.42% Intraday chart for Intensity Therapeutics, Inc. -3.66% -44.69%
Jul. 09 Intensity Therapeutics, Inc. Announces First Patient Dosed in Its Global Randomized, Phase 3 Study (Invincible-3) in Metastatic Soft Tissue Sarcoma CI
Jul. 01 Intensity Therapeutics, Inc.(NasdaqCM:INTS) dropped from Russell Microcap Value Index CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
PR
Intensity Therapeutics, Inc. Announces First Patient Dosed in Its Global Randomized, Phase 3 Study (Invincible-3) in Metastatic Soft Tissue Sarcoma
CI
Intensity Therapeutics, Inc.(NasdaqCM:INTS) dropped from Russell Microcap Value Index
CI
Intensity Therapeutics, Inc.(NasdaqCM:INTS) dropped from Russell 3000E Value Index
CI
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
PR
Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors
CI
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe
AQ
Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK
CI
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial
MT
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
PR
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
CI
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Intensity Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
PU
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors
CI
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
PR
Portage biotech completes monetization of intensity therapeutics shares
AQ
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
AQ
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INTS Stock
  4. News Intensity Therapeutics, Inc.